Search

Francois Pepin Phones & Addresses

  • 381 Villa St, Mountain View, CA 94041
  • San Bruno, CA
  • San Francisco, CA
  • Berkeley, CA
  • 2481 Catalpa Way, San Bruno, CA 94066

Resumes

Resumes

Francois Pepin Photo 1

Senior Ml Software Engineer

View page
Location:
348 Hatch Dr, Foster City, CA 94404
Industry:
Biotechnology
Work:
Sequenta Inc since 2011
Scientist

Lawrence Berkeley National Laboratory 2010 - 2011
Post-doctoral Fellow

McGill University Jan 2003 - Apr 2010
PhD student
Education:
McGill University 1998 - 2008
PhD, Biochemistry
Skills:
Bioinformatics
R
Java
Perl
Statistics
Biostatistics
Unix
Data Analysis
Sequence Analysis
Microarray Analysis
Shell Scripting
Cancer
Computational Biology
Systems Biology
Cell Biology
Molecular Biology
Genetics
Genomics
Data Mining
Biochemistry
Cancer Research
Dna Sequencing
Machine Learning
Sequencing
Languages:
English
French
Francois Pepin Photo 2

Francois Pepin

View page

Publications

Us Patents

Gene Expression Panel For Breast Cancer Prognosis

View page
US Patent:
20140018253, Jan 16, 2014
Filed:
Apr 5, 2013
Appl. No.:
13/857536
Inventors:
The Regents of the University of California - , US
Oregon Health and Science University - , US
Francois Pepin - San Bruno CA, US
Paul T. Spellman - Portland OR, US
Joe W. Gray - Lake Oswego OR, US
Assignee:
Oregon Health and Science University - Portland OR
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68
G06F 19/00
US Classification:
506 9, 506 16, 435 612, 435 792, 702 20
Abstract:
The invention described in the application relates to a panel of gene expression markers for node-negative, ER-positive, HER2-negative breast cancer patients. The invention thus provides methods and compositions, e.g., kits and/or microarrays, for evaluating gene expression levels of the markers and methods of using such gene expression levels to evaluate the likelihood of relapse of a node-negative, ER-positive, HER2-negative breast cancer patient. Such information can be used in determining treatment options for patients.

Rare Clonotypes And Uses Thereof

View page
US Patent:
20130196328, Aug 1, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/834794
Inventors:
Francois Pepin - San Bruno CA, US
Malek Faham - Pacifica CA, US
Martin Moorhead - San Mateo CA, US
Assignee:
Sequenta, Inc. - South San Francisco CA
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
The invention is directed to a method of selecting disease-correlated clonotypes that have a reduced likelihood of producing a false positive signal of relapse when, used to monitor minimal residual disease. In accordance with the invention, candidate correlating clonotype are obtained from a patient, the rarity of each is determined either by comparison with a clonotype database or a clonotype model, and one or more of the rarest of such clonotypes are used to monitor the minimal residual disease.

Gene Expression Panel For Breast Cancer Prognosis

View page
US Patent:
20180066321, Mar 8, 2018
Filed:
Sep 8, 2017
Appl. No.:
15/699804
Inventors:
- Oakland CA, US
- Portland OR, US
Francois Pepin - San Bruno CA, US
Paul T. Spellman - Portland OR, US
Joe W. Gray - Lake Oswego OR, US
International Classification:
C12Q 1/68
G06F 19/00
Abstract:
The invention described in the application relates to a panel of gene expression markers for node-negative, ER-positive, HER2-negative breast cancer patients. The invention thus provides methods and compositions, e.g., kits and/or microarrays, for evaluating gene expression levels of the markers and methods of using such gene expression levels to evaluate the likelihood of relapse of a node-negative, ER-positive, HER2-negative breast cancer patient. Such information can be used in determining treatment options for patients.

Predicting Relapse Of Chronic Lymphocytic Leukemia Patients Treated By Allogeneic Stem Cell Transplantation

View page
US Patent:
20150247201, Sep 3, 2015
Filed:
May 30, 2013
Appl. No.:
14/404435
Inventors:
Malek Faham - South San Francisco CA, US
Victoria Carlton - South San Francisco CA, US
Martin Moorhead - South San Francisco CA, US
Francois Pepin - South San Francisco CA, US
International Classification:
C12Q 1/68
Abstract:
The invention is directed to a prognostic indicator for CLL patients who have undergone an allogeneic stem cell transplant (SCT). The indicator is based on a method of monitoring levels and changes in levels of correlating clonotypes of the CLLs at successive time points. The prognostic indicator applies to patients who have survived for at least one year from an allogeneic SCT and includes criteria based on the following two measurements: (a) frequency of CLL correlating clonotypes (e.g. in terms of number per 10clonotypes) in an initial clonotype profile (from peripheral blood), and (b) fold change in such CLL correlating clonotype number between such initial measurement and a successively measured clonotype profile.
Francois Te Pepin from Mountain View, CA, age ~45 Get Report